17:10 , Nov 16, 2018 |  BC Week In Review  |  Company News

Michigan to begin talks with drug manufacturers for value-based deals

With a stamp of approval from CMS on Nov. 14, Michigan joins Oklahoma as one of the only two states with the agency's OK to negotiate Medicaid outcomes-based pricing agreements with drug manufacturers. "Michigan’s waiver...
23:55 , Nov 14, 2018 |  BC Extra  |  Politics & Policy

Michigan to begin talks with drug manufacturers for value-based deals

With a stamp of approval from CMS on Wednesday, Michigan joins Oklahoma as one of the only two states with the agency's OK to negotiate Medicaid outcomes-based pricing agreements with drug manufacturers. "Michigan’s waiver will...
02:50 , Oct 20, 2018 |  BioCentury  |  Product Development

New shops for value-based deals

Value-based payment models are starting to appear beyond the high-profile insurers and PBMs that have dominated the scene, with a series of deals struck since August by the Oklahoma Health Care Authority and the University...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
17:44 , Sep 7, 2018 |  BC Week In Review  |  Company News

Alkermes in pay-for-performance deal

Alkermes plc (NASDAQ:ALKS) signed a contract with UPMC Health Plan for opioid antagonist Vivitrol naltrexone that links reimbursement of the drug to positive clinical outcomes when treating opioid dependence. Alkermes spokesperson Matthew Henson did not...
18:07 , Aug 31, 2018 |  BC Week In Review  |  Company News

Alkermes, Oklahoma negotiating value-based Medicaid purchasing agreements

The Oklahoma Health Care Authority (OHCA) said it has signed its first contract to negotiate value-based Medicaid purchasing agreements with Alkermes plc (NASDAQ:ALKS) for schizophrenia drug Aristada aripiprazole lauroxil. OHCA is also close to agreements...
15:12 , Aug 31, 2018 |  BC Extra  |  Company News

Alkermes in pay-for-performance deal

Alkermes plc (NASDAQ:ALKS) signed a contract with UPMC Health Plan for opioid antagonist Vivitrol naltrexone that links reimbursement of the drug to positive clinical outcomes when treating opioid dependence. Alkermes spokesperson Matthew Henson did not...
21:59 , Aug 24, 2018 |  BC Extra  |  Company News

Alkermes, Oklahoma negotiating value-based Medicaid purchasing agreements

The Oklahoma Health Care Authority (OHCA) said it has signed its first contract to negotiate value-based Medicaid purchasing agreements with Alkermes plc (NASDAQ:ALKS) for schizophrenia drug Aristada aripiprazole lauroxil. OHCA is also close to agreements...
19:25 , Jul 5, 2018 |  BC Week In Review  |  Clinical News

Alkermes' Aristada Initio approved for schizophrenia

FDA approved Aristada Initio aripiprazole lauroxil from Alkermes plc (NASDAQ:ALKS) in combination with oral aripiprazole to initiate treatment of schizophrenia in adults. The company expects to launch the product mid-July. Aristada Initio is an extended-release...
19:21 , Jul 2, 2018 |  BC Extra  |  Company News

New dose regimen for Alkermes' aripiprazole approved

Alkermes plc (NASDAQ:ALKS) said FDA approved Aristada Initio aripiprazole lauroxil in combination with oral aripiprazole for adult schizophrenia patients initiating treatment with Aristada. Aristada previously required three weeks of oral aripiprazole supplementation following the first...